Yung H. Chyung
Fortune : 470 800 $ au 30/06/2026
Fortune : 470 800 $ au 30/06/2026
Yung H.
Chyung formerly worked at Dyax Corp., as Vice President-Medical Research from 2011 to 2016, Scholar Rock, Inc., as Chief Medical Officer from 2016 to 2022, Keros Therapeutics, Inc., as Chief Medical Officer from 2024 to 2025, Scholar Rock Holding Corp., as Chief Medical Officer from 2016 to 2022, and Tourmaline Bio, Inc., as Chief Medical Officer from 2023 to 2024.
Dr. Chyung received his doctorate degree in 2003 from Harvard Medical School and undergraduate degree in 1997 from Harvard College.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 18/02/2025 | 44 000 ( 0,22% ) | 470 800 $ | 30/06/2026 |
| Sociétés | Poste | Fin |
|---|---|---|
| KEROS THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/08/2025 |
| SCHOLAR ROCK HOLDING CORPORATION | Directeur Technique/Scientifique/R&D | 30/06/2022 |
Scholar Rock, Inc.
Scholar Rock, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Directeur Technique/Scientifique/R&D | 30/06/2022 |
| DYAX CORP. | Corporate Officer/Principal | 01/02/2016 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 6 |
|---|---|
Dyax Corp.
Dyax Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that engages in development and commercialization of novel biotherapeutics | Health Technology |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard College
Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Scholar Rock, Inc.
Scholar Rock, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Keros Therapeutics, Inc.
Keros Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics for muscle diseases | Health Technology |
Scholar Rock Holding Corp.
Scholar Rock Holding Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that focused on the discovery, development and delivery medicines for neuromuscular, cardiometabolic disorders, cancer, fibrosis and iron-restricted anemia | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national